News
OABI
4.680
+0.21%
0.010
Press Release: OmniAb to Report First Quarter 2024 Financial Results on May 9
OmniAb to Report First Quarter 2024 Financial Results on May 9, 2024. The company will report financial results for the three months ended March 31, 2024 after the close of the U.S. Financial markets. OmniAb will hold a conference call and webcast to discuss financial results on Thursday, May 9. OmniAb licenses cutting edge discovery technology to the pharmaceutical and biotech industry.
Dow Jones · 23h ago
Weekly Report: what happened at OABI last week (0415-0419)?
Weekly Report · 1d ago
Weekly Report: what happened at OABI last week (0408-0412)?
Weekly Report · 04/15 10:25
OMNIAB INC <OABI.O>: LEERINK PARTNERS RAISES TARGET PRICE TO $13 FROM $11
Reuters · 04/12 12:03
RBC Capital Remains a Buy on OmniAb (OABI)
OmniAb has an analyst consensus of Strong Buy, with a price target of $9.67. RBC Capital analyst Conor McNamara maintained a Buy rating on OmniAb. The company’s shares closed yesterday at $5.31. The corporate insider sentiment is positive on the stock.
TipRanks · 04/09 01:46
Weekly Report: what happened at OABI last week (0401-0405)?
Weekly Report · 04/08 10:28
Insiders Load Up on These 2 Stocks — Here’s Why You Should Follow
TipRanks · 04/03 09:44
Weekly Report: what happened at OABI last week (0325-0329)?
Weekly Report · 04/01 10:27
OmniAb Price Target Maintained With a $10.00/Share by Truist Securities
Dow Jones · 03/26 13:28
OmniAb Is Maintained at Buy by Truist Securities
Dow Jones · 03/26 13:28
Truist Securities Maintains Buy on OmniAb, Maintains $10 Price Target
Benzinga · 03/26 13:18
Over $1M Bet On OmniAb? Check Out These 3 Stocks Insiders Are Buying
U.S. Stocks closed lower on Monday but there were a few notable insider trades. Hallador Energy Company and Pacific Premier Bancorp made notable insider purchases. When insiders purchase shares, it indicates confidence in the company's prospects or that they view the stock as a bargain.
Benzinga · 03/26 12:40
Monday 3/25 Insider Buying Report: LILA, OABI
NASDAQ · 03/25 15:44
Craig-Hallum Sticks to Their Buy Rating for OmniAb (OABI)
TipRanks · 03/25 14:25
Weekly Report: what happened at OABI last week (0318-0322)?
Weekly Report · 03/25 10:29
OmniAb Price Target Maintained With a $8.00/Share by Benchmark
Dow Jones · 03/22 17:42
Benchmark Reiterates Buy on OmniAb, Maintains $8 Price Target
Benzinga · 03/22 17:32
Benchmark Co. Reaffirms Their Buy Rating on OmniAb (OABI)
TipRanks · 03/22 11:18
OmniAb Price Target Maintained With a $11.00/Share by HC Wainwright & Co.
Dow Jones · 03/21 15:37
HC Wainwright & Co. Reiterates Buy on OmniAb, Maintains $11 Price Target
Benzinga · 03/21 15:30
More
Webull provides a variety of real-time OABI stock news. You can receive the latest news about OmniAb, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About OABI
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate the development of human therapeutic candidates. The Company’s OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications through a common light chain approach, and OmniTaur features structural attributes of cow antibodies for complex targets. The Company's OmniChicken and OmniClic offer affinity-matured antibodies in an evolutionarily distant chicken host environment, which can deliver a diverse repertoire of antibody panels to conserved therapeutic target antigens.